Skip to main content
. 2021 Jun 23;16(1):69–87. doi: 10.1002/1878-0261.13021

Table 1.

Clinicopathological characteristics.

Characteristics n
Median age at diagnosis of metastasis (range) 54 (24–89)
Menopausal status Premenopausal 68 (38.6%)
Postmenopausal 97 (55.1%)
Unknown 10 (5.7%)
Male 1 (0.6%)
Type of metastasis De novo metastasis 27 (15.3%)
Relapsed 146 (83.0%)
Unknown 3 (1.7%)
Total number of metastatic sites < 3 76 (43.2%)
≥ 3 90 (51.1%)
Unknown 10 (5.7%)
Site of metastatic biopsy Locoregional 50 (27.2%)
Distant 134 (72.8%)
Metastatic spread Bone‐only 15 (8.5%)
Visceral 145 (82.4%)
Organ of biopsy Bone 33 (17.9%)
Brain 22 (12.0%)
Breast 24 (13.0%)
Liver 31 (16.9%)
Lung 13 (7.1%)
Lymph node 16 (8.7%)
Muscle 2 (1.1%)
Ovary 4 (2.2%)
Peritoneum 2 (1.1%)
Pleura 10 (5.4%)
Skin 27 (14.7%)
IHC group of the metastatic biopsy HR+/HER2‐ 100 (54.4%)
HER2+ 18 (9.8%)
TNBC 53 (28.8%)
Unknown 13 (7.1%)
PAM50 molecular subtype of the metastatic biopsy Luminal A 30 (16.3%)
Luminal B 47 (25.5%)
HER2‐enriched 42 (22.8%)
Basal‐like 54 (29.4%)
Normal‐like 11 (6.0%)
Previous (neo)adjuvant treatment 129 (73.3%)
Median number of lines of treatment for metastatic disease (range) 3 (0–13)
Treatments received in the metastatic setting Endocrine therapy 111 (63.1%)
CDK4/6 inhibitors 84 (47.7%)
Anti‐HER2 therapies 28 (15.9%)
Chemotherapy 125 (71.0%)
Immunotherapy 10 (5.7%)
Everolimus 22 (12.5%)
PI3K inhibitors 18 (10.2%)
AKT inhibitors 2 (1.1%)
Bevacizumab 15 (8.5%)
PARP inhibitors 3 (1.7%)
Radiotherapy 111 (63.1%)